Sorrento Therapeutics, Inc.

383 articles about Sorrento Therapeutics, Inc.

• Sorrento Therapeutics, Inc. Announces Reverse Split of Common Stock

  8/1/2013

• Sorrento Therapeutics, Inc. and Ben-Gurion University of the Negev Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies

  7/9/2013

• Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th International Nanomedicine Conference in Sydney, Australia

  7/1/2013

• Sorrento Therapeutics, Inc. Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit

  6/24/2013

• Sorrento Therapeutics, Inc. and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base

  6/21/2013

• Sorrento Therapeutics, Inc. Receives Frost & Sullivan's 2013 Global Investment Opportunity Award in Oncology

  6/6/2013

• Sorrento Therapeutics, Inc. to Present at the Jefferies and Co. 2013 Global Healthcare Conference in New York City

  5/31/2013

• Sorrento Therapeutics, Inc. and IGDRASOL Present Phase I Clinical Data for the Combination of CynviloqTM (paclitaxel polymeric micelle) plus gemcitabine for Treatment of Advanced Pancreatic Cancer at American Society of Clinical Oncology 2013 (booth #2090

  5/28/2013

• Sorrento Therapeutics, Inc. Announces Its Approach to Developing Human Antibody Therapeutics Against MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases

  5/20/2013

• Sorrento Therapeutics, Inc. and IGDRASOL Announce the Acquisition of Exclusive Distribution Rights to Cynviloq&#0153 for the European Union

  5/14/2013

• Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain

  4/8/2013

• Sorrento Therapeutics, Inc. and IGDRASOL Announce Three Presentations on Cynviloq&0153 (IG-001; Paclitaxel Polymeric Micelle) at the American Association for Cancer Research (AACR) Meeting

  4/1/2013

• Sorrento Therapeutics, Inc. Signs Exclusive Option to Acquire IGDRASOL

  3/7/2013

• Sorrento Therapeutics, Inc. Acquires Rights to Produce Recombinant Intravenous Immunoglobulins (rIVIG)

  1/8/2013

• Sorrento Therapeutics, Inc. Awarded Third Phase I STTR Grant

  6/8/2012

• Sorrento Therapeutics, Inc. Awarded Phase I STTR Grant for C. difficile Program

  7/29/2011

• Sorrento Therapeutics, Inc.' Innovative Approach to Developing Vaccines and Therapeutics for MRSA Receives Continued Support From the National Institute of Allergy And Infectious Diseases (NIAID)

  7/6/2011

• Sorrento Therapeutics, Inc. Awarded National Institutes of Health (NIH) Grant for MRSA Program

  5/21/2010

• Sorrento Therapeutics, Inc. Announces Completion of Diverse Library of Full-Length, Fully Human Antibodies

  4/14/2010

• Sorrento Therapeutics, Inc. Announces Antibody Discovery and Development Alliance for the Prevention and Treatment of MRSA Infections

  1/11/2010